asco: current data and outlook for targeting her2 in gastrointestinal cancer
Published 4 years ago • 12 plays • Length 6:17Download video MP4
Download video MP3
Similar videos
-
14:55
asco: perioperative targeting of her2 for gastroesophageal cancer
-
13:32
asco: new data and implications for immunotherapy in gastric cancer
-
5:25
asco: promising results for trastuzumab deruxtecan for her2 gastric cancer
-
1:18:52
her2-positive gastrointestinal cancers: new evidence and practical guidance with targeted agents
-
34:31
chair's take: her2-targeted and other agents for gastric cancer
-
6:38
potential new options for patients with her2 gastric cancer
-
13:47
asco gi: new data on fgfr inhibition with frontline bemarituzumab in gastroesophageal tumors
-
1:07:30
personalizing gastric cancer care with her2-targeted and other novel therapies
-
0:54
targeted treatment for gastric cancer beyond her2
-
15:48
targeting her 2 and angiogenesis in gastric cancer: what is the impact?
-
7:00
asco 2009: standard treatment plus trastuzumab for her2 gastric cancer
-
8:17
metastatic gastric cancer: indications and impact of targeting the her2 pathway?
-
14:29
targeting her 2 and angiogenesis in gastric cancer: what is the impact
-
2:59
clinical implications of her2 in gi cancers
-
2:38
her2 in gastric cancer
-
2:19
asco gi 2021: her2-positive gastric cancer, polo and key trials in progress
-
3:24
cap-ascp-asco her2 testing and clinical decision-making in gastroesophageal adenocarcinoma guideline
-
59:18
optimizing novel her2-targeted therapies and other agents in gastric cancer care
-
34:27
fulfilling the potential of her2-targeting in colorectal cancer: update on detection and management